Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Stockholders to Learn More About the Investigation ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) on behalf of TransMedics stockholders. Our investigation concerns whether TransMedics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company iss ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

SAN FRANCISCO, Jan. 14, 2025 /PRNewswire/ -- Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a damaging report by activist short-seller Scorpion Capital. TransMedics' stock price has dropped $9.84, or 13%, since Scorpion released a report, titled "Walk Like An Egyptian," leveling serious allegations against the company, including fraud, organ trafficking, and off-label device misuse.Hagens Berman has opened an investigation in ...

ANDOVER, Mass., Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025. In response, the company issued the following statement: We strongly believe that the claims made in the Scorpion Capital report ...

In this video, I will talk about TransMedics (TMDX -5.16%) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Jan. 10, 2025. The video was published on Jan. 10, 2025. ...

Shares of TransMedics Group (TMDX -11.36%) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics.Scorpion stated in its report, "TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients -- the terminally ill, desperate for an organ." The short seller alleged that Tr ...

Shares of Transmedics (TMDX 9.47%) fell 28.1% in December, according to data from S&P Global Market Intelligence.The stock was already down significantly from its highs heading into the month following a weaker-than-expected October earnings report, so December events added insult to injury. Here's what happened to the former high flier. A cruel DecemberOn Dec. 2, Transmedics announced it had appointed Gerardo Hernandez as CFO, replacing current CFO Stephen Gordon effective immediately. Gordon will stay on ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

Leading organ transplant technology provider TransMedics (TMDX 3.90%) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of "only" 64% in its latest quarter -- while lowering guidance for a 35% increase in the upcoming fourth quarter -- the company has seen its stock plummet roughly 63% from its highs.As substantial as TransMedics' stock sell-off has been, its underlying business is by no means 63% worse. And remember, this adverse ...